U.S. FDA Approves Radicava (Edaravone) to Treat ALS
Topic: FDA News and Approvals
Author: U.S. Food and Drug Administration - Contact: fda.gov
Published: 2017/05/06
Contents: Summary - Introduction - Main Item - Related Topics
Synopsis: U.S. Food and Drug Administration approves Radicava (edaravone) to treat amyotrophic lateral sclerosis, commonly referred to as Lou Gehrig's disease.
Introduction
The U.S. Food and Drug Administration has approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig's disease.
Main Item
"After learning about the use of edaravone to treat ALS in Japan, we rapidly engaged with the drug developer about filing a marketing application in the United States," said Eric Bastings, M.D., deputy director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research. "This is the first new treatment approved by the FDA for ALS in many years, and we are pleased that people with ALS will now have an additional option."
ALS is a rare disease that attacks and kills the nerve cells that control voluntary muscles. Voluntary muscles produce movements such as chewing, walking, breathing and talking. The nerves lose the ability to activate specific muscles, which causes the muscles to become weak and leads to paralysis. ALS is progressive, meaning it gets worse over time. The Centers for Disease Control and Prevention estimates that approximately 12,000-15,000 Americans have ALS. Most people with ALS die from respiratory failure, usually within three to five years from when the symptoms first appear.
Radicava is an intravenous infusion given by a health care professional. It is administered with an initial treatment cycle of daily dosing for 14 days, followed by a 14-day drug-free period. Subsequent treatment cycles consist of dosing on 10 of 14 days, followed by 14 days drug-free.
The efficacy of edaravone for the treatment of ALS was demonstrated in a six-month clinical trial conducted in Japan. In the trial, 137 participants were randomized to receive edaravone or placebo. At Week 24, individuals receiving edaravone declined less on a clinical assessment of daily functioning compared to those receiving a placebo.
The most common adverse reactions reported by clinical trial participants receiving edaravone were bruising (contusion) and gait disturbance.
Radicava is also associated with serious risks that require immediate medical care, such as hives, swelling, or shortness of breath, and allergic reactions to sodium bisulfite, an ingredient in the drug. Sodium bisulfite may cause anaphylactic symptoms that can be life-threatening in people with sulfite sensitivity.
The FDA granted this drug orphan drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases.
The FDA granted approval of Radicava to Mitsubishi Tanabe Pharma America, Inc.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency is also responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
Explore Related Topics
1 - Cognoa ASD Diagnosis Aid Approved for Marketing by FDA - Cognoa ASD Diagnosis Aid is an aid for diagnosis of ASD in patients 18 months - 5 years of age who are at risk of developmental delay based on concerns of a parent, caregiver, or health care provider.
2 - Neurolutions IpsiHand Upper Extremity Rehabilitation System - U.S. FDA authorizes marketing of Neurolutions IpsiHand Upper Extremity Rehabilitation System to facilitate muscle rehabilitation in stroke patients.
3 - Safety and Effectiveness of Consumer Hand Sanitizers - U.S. FDA completes series of actions on review of OTC antiseptic active ingredients and issues final rule on safety and effectiveness of consumer hand sanitizers.
4 - Generic Version of EpiPen Approved by U.S. FDA - Teva Pharmaceuticals USA gains approval to market its generic epinephrine auto-injector in 0.3 mg and 0.15 mg strengths for emergency treatment of allergic reactions in adults and pediatric patients who weigh more than 33 pounds.
5 - Scammers Target Consumers with Fake FDA Warning Letters - U.S. FDA warns consumers about criminals forging FDA warning letters to target people who tried to purchase medicines online or over the phone.
Page Information, Citing and Disclaimer
Disabled World is a comprehensive online resource that provides information and news related to disabilities, assistive technologies, and accessibility issues. Founded in 2004 our website covers a wide range of topics, including disability rights, healthcare, education, employment, and independent living, with the goal of supporting the disability community and their families.
Cite This Page (APA): U.S. Food and Drug Administration. (2017, May 6). U.S. FDA Approves Radicava (Edaravone) to Treat ALS. Disabled World. Retrieved October 15, 2024 from www.disabled-world.com/medical/pharmaceutical/fda/radicava.php
Permalink: <a href="https://www.disabled-world.com/medical/pharmaceutical/fda/radicava.php">U.S. FDA Approves Radicava (Edaravone) to Treat ALS</a>: U.S. Food and Drug Administration approves Radicava (edaravone) to treat amyotrophic lateral sclerosis, commonly referred to as Lou Gehrig's disease.
Disabled World provides general information only. Materials presented are never meant to substitute for qualified medical care. Any 3rd party offering or advertising does not constitute an endorsement.